Bayh–Dole Act

Bayh–Dole Act
U.S. Government · Public domain · source
Title	Bayh–Dole Act
Enacted by	98th United States Congress
Effective date	1980
Public law	Public Law 96–517
Sponsors	Birch Bayh, Bob Dole
Cite	35 U.S.C. §§ 200–212

Bayh–Dole Act. The Bayh–Dole Act is landmark United States legislation enacted in 1980 that altered patent ownership and commercialization of inventions arising from federally funded research. The statute shifted rights from federal agencies to nonprofit organizations and small businesses represented by sponsors such as Birch Bayh and Bob Dole, provoking extensive debate among stakeholders including National Institutes of Health, National Science Foundation, Department of Energy, Stanford University, and Massachusetts Institute of Technology.

Background and Legislative History

During the 1960s and 1970s, reports by entities like National Academy of Sciences, National Science Foundation, and panels associated with Office of Scientific and Technical Information noted limited commercial deployment of inventions from programs such as the Manhattan Project legacy and ARPA initiatives. Legislative hearings featured testimony from representatives of Association of American Universities, American Association for the Advancement of Science, General Electric, and advocates from Small Business Administration and Industrial Research Institute, prompting sponsors Birch Bayh and Bob Dole to craft a bill modeled against experiences at institutions like Stanford University and companies including IBM and DuPont. Debates in the United States Senate and United States House of Representatives referenced precedents such as the Sherman Antitrust Act discussions and invoked analyses by commentators associated with Brookings Institution, Heritage Foundation, and American Enterprise Institute.

Key Provisions and Mechanisms

The statute permits nonprofit organizations and small businesses to elect title to inventions conceived or first reduced to practice in the performance of federally funded research, subject to government rights including a nonexclusive license retained by agencies such as National Institutes of Health and Department of Defense. It mandates obligations like requiring organizations to file patent applications with the United States Patent and Trademark Office, grant the federal government a nonexclusive, nontransferable, paid-up license, and provide the agency with "march-in" rights exemplified in discussions involving National Institutes of Health and controversies tied to firms like Roche and Novartis. The Act requires reporting, preference for manufacturing in the United States as debated by United States Congress committees, and stipulates revenue-sharing frameworks implemented at universities including University of California, Columbia University, and Harvard University.

Implementation and Administration

Implementation involves federal agencies such as National Institutes of Health, National Science Foundation, Department of Energy, and Department of Defense issuing regulations and policy guidance administered by offices including the Office of Technology Transfer at National Institutes of Health and university technology transfer offices at institutions like Stanford University, Massachusetts Institute of Technology, Johns Hopkins University, University of Michigan, and Yale University. Coordination with the United States Patent and Trademark Office and oversight from Congressional Research Service, Government Accountability Office, and executive branch offices such as the Office of Management and Budget shaped implementation practices, while university administrators, chief technology officers, and corporate partners like Pfizer and GlaxoSmithKline negotiated licensing agreements and startup formation.

Impact on Innovation and Technology Transfer

Scholars from Harvard University, Stanford University, Massachusetts Institute of Technology, and University of California report growth in patenting, licensing revenues, and startup creation linked to federally funded research, with notable examples involving technologies commercialized by firms like Genentech, Amgen, and Biogen. Analyses by National Bureau of Economic Research, Brookings Institution, and Kauffman Foundation quantify effects on entrepreneurship, university spinouts, and regional innovation ecosystems exemplified in regions such as Silicon Valley, Research Triangle Park, and Boston, Massachusetts. Sectoral impacts reached biotechnology, pharmaceuticals, and information technology firms including Roche, Novartis, IBM, and Microsoft through transfer pathways mediated by technology transfer offices at Columbia University and University of Wisconsin–Madison.

Criticisms, Legal Challenges, and Reforms

Critics including scholars at American Association for the Advancement of Science, advocacy groups like Public Citizen, and commentators from The Lancet and New England Journal of Medicine argue the statute contributed to higher prices for drugs commercialized by entities such as Genentech and Amgen and to restricted access debates involving University of California technologies. Legal challenges and policy disputes reached agencies including National Institutes of Health and courts such as the United States Court of Appeals for the Federal Circuit, with controversies over "march-in" rights invoked in cases involving Roche and petitions reviewed by National Institutes of Health leadership. Legislative proposals and administrative reforms debated in the United States Congress and advised by Government Accountability Office and Congressional Research Service have sought adjustments to licensing terms, transparency, and equitable licensing models championed by advocates including AMP and public-interest organizations.

International Influence and Comparative Models

The statute influenced policy reforms and comparative models adopted by jurisdictions including the United Kingdom, Germany, Japan, Canada, Australia, and members of the European Union, prompting adaptations by institutions such as Max Planck Society, CNRS, University of Tokyo, and CSIRO. International organizations like the Organisation for Economic Co-operation and Development and World Intellectual Property Organization analyzed transnational technology transfer frameworks, leading to diverse approaches such as sovereign ownership models in parts of Europe and university-centric regimes in countries exemplified by United Kingdom and Japan.

Category:United States federal legislation Category:Intellectual property law Category:Technology transfer